SOURCE: Healtheuniverse, Inc.

February 22, 2007 09:03 ET

Healtheuniverse and C.I.C.R.S. Expand Clinical Trial Collaboration Agreement for Commercialization of Adult Stem Cell Therapies

Long Term Strategic Alliance Strengthens Clinical Trial Capabilities for Stem Cell Therapies in the $15 Billion Worldwide Plastic Surgery and Cosmetic Surgery Market

COVINA, CA -- (MARKET WIRE) -- February 22, 2007 -- Healtheuniverse, Inc. (PINKSHEETS: HLUN), a biotechnology development firm engaged in research, development and commercialization of regenerative medicine therapies utilizing non-embryonic adult stem cells, announced today an expansion of the clinical trial collaboration agreement between Healtheuniverse and The California Institute of Cosmetic and Reconstructive Surgery (C.I.C.R.S.). The strategic alliance is focused on the expansion of both Companies' individual strengths leveraging Healtheuniverse's patented stem cell technology and research and development capabilities, and C.I.C.R.S.'s clinical trial capabilities in a joint effort to commercialize the first non-embryonic stem cell therapy in the field of plastic, reconstructive, and cosmetic surgery.

"Our collaboration with C.I.C.R.S. is another critical component in our global commercialization plans for adult stem cell therapies," stated Dr. Vipul Dev, M.D., Chief Executive Officer of Healtheuniverse, Inc. "Our goal is to offer not only the first stem cell therapy in the field of plastic, reconstructive and cosmetic surgery but to also lead the medical field in commercializing stem cell therapeutic uses in disease related commercial applications."

About The California Institute of Cosmetic and Reconstructive Surgery (C.I.C.R.S.)

Services at The California Institute of Cosmetic & Reconstructive Surgery range from the latest techniques in Cosmetic Surgery to extensive new developments in the field of Reconstructive Surgery. The Institute performs Cosmetic Surgery such as breast augmentation, facelifts, liposuction, and rhinoplasty, as well as extensive Reconstructive Surgery for breast cancer, burn victims, trauma victims, chronic wounds, skin cancer, and hand surgery.

About HEALTHeUNIVERSE, Inc.

HEALTHeUNIVERSE, Inc. is engaged in research, development and commercialization of regenerative medicine therapies utilizing non-embryonic adult stem cells for use in plastic and reconstructive surgery, orthopedic surgery, vascular surgery, cardiac surgery, and wound care. Healtheuniverse strives to be the first to commercialize the use of regenerative medicine in plastic and reconstructive surgery and to develop therapeutic uses in disease related commercial applications. More information on Healtheuniverse is available online at http://healtheuniverse.com/

Safe Harbor Statement

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Healtheuniverse, Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Contact Information

  • For more information, please contact:
    Healtheuniverse, Inc.
    Investor Relations
    800-719-7424
    Email Contact